Showing results (201-210 of 469) with videos related to
Sort By:
Pageof 47
The Oncologist|November 25, 2016
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)Preet Paul Singh, Qian Shi, Nathan R Foster, et al.Molecular Therapy Oncolytics|December 2, 2022
Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancerMarshall D Behrens, Robert J Stiles, Gennett M Pike, et al.Cancer|June 15, 2007
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancerAmanda C Ashley, Daniel J Sargent, Steven R Alberts, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trialsDaniel Sargent, Alberto Sobrero, Axel Grothey, et al.Molecular Cancer Research : MCR|March 11, 2018
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal CancersMohamed E Salem, Alberto Puccini, Axel Grothey, et al.Oncotarget|June 25, 2019
Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfallAnn M Moyer, Jia Yu, Jason P Sinnwell, et al.Clinical Colorectal Cancer|August 8, 2007
Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248Steven R Alberts, George P Kim, Michelle R Mahoney, et al.Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.The Oncologist|June 15, 2020
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast CancerMatthew P Goetz, Miguel Martin, Eriko Tokunaga, et al.Breast Cancer Research : BCR|August 24, 2021
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialPatrick Neven, Hope S Rugo, Sara M Tolaney, et al.Pageof 47